Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5274083
Max Phase: Preclinical
Molecular Formula: C35H52O10
Molecular Weight: 632.79
Associated Items:
ID: ALA5274083
Max Phase: Preclinical
Molecular Formula: C35H52O10
Molecular Weight: 632.79
Associated Items:
Canonical SMILES: C[C@@H]1C[C@]2(OC(O)[C@@]3(C)O[C@@H]23)O[C@H]2C[C@@]3(C)[C@@H]4CC[C@H]5C(C)(C)[C@@H](O[C@@H]6OC[C@@H](O)[C@H](O)[C@H]6O)CC[C@@]56C[C@@]46CC(=O)[C@]3(C)[C@@H]12
Standard InChI: InChI=1S/C35H52O10/c1-16-11-35(27-32(6,44-27)28(40)45-35)43-18-12-30(4)20-8-7-19-29(2,3)22(42-26-25(39)24(38)17(36)14-41-26)9-10-33(19)15-34(20,33)13-21(37)31(30,5)23(16)18/h16-20,22-28,36,38-40H,7-15H2,1-6H3/t16-,17-,18+,19+,20+,22+,23+,24+,25-,26+,27-,28?,30+,31-,32+,33-,34+,35-/m1/s1
Standard InChI Key: NHTQFQAXFISOPP-BVKNZIPKSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 632.79 | Molecular Weight (Monoisotopic): 632.3560 | AlogP: 2.67 | #Rotatable Bonds: 2 |
Polar Surface Area: 147.44 | Molecular Species: NEUTRAL | HBA: 10 | HBD: 4 |
#RO5 Violations: 1 | HBA (Lipinski): 10 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 11.07 | CX Basic pKa: | CX LogP: 2.87 | CX LogD: 2.87 |
Aromatic Rings: 0 | Heavy Atoms: 45 | QED Weighted: 0.26 | Np Likeness Score: 3.22 |
1. Zhang H, Chen Y, Huang S, Xiao WW, Qiu MH, Shao LD, Chen CH, Li D.. (2023) Development of actein derivatives as potent anti-triple negative breast cancer agents., 89 [PMID:37121522] [10.1016/j.bmcl.2023.129307] |
Source(1):